KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KALV 14.47 -0.92(-5.98%)
Will KALV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here's Why You Should Invest in Alpine (ALPN) Stock Now
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for KALV
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KalVista begins trial for sebetralstat in children with hereditary angioedema
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch